Trung tâm Thông tin - Thư viện Trường Đại học Y Dược Hải Phòng

NLM	C22
Tác giả CN	Phan Hữu Phúc
Nhan đề	Effectiveness and safety of shortened intensive treatment for children with tuberculous meningitis (SURE): a protocol for a phase 3 randomised controlled trial evaluating 6 months of antituberculosis therapy and 8 weeks of aspirin in Asian and African children with tuberculous meningitis
Thông tin xuất bản	2025
Thông tin xuất bản	BMJ
Tóm tắt	400 children (aged 29 days to <18 years) with clinically diagnosed TBM will be randomised, using a factorial design, to either a 24-week intensified regimen (isoniazid (20 mg/kg), rifampicin (30 mg/kg), pyrazinamide (40 mg/kg) and levofloxacin (20 mg/kg)) or the standard 48-week ATT regimen and 8 weeks of high-dose aspirin or placebo. The primary outcome for the first randomisation is all-cause mortality, and for the second randomisation is the paediatric modified Rankin Scale (mRS), both at 48 weeks. Nested substudies include pharmacokinetics, pharmacogenetics, pathophysiology, diagnostics and prognostic biomarkers, in-depth neurodevelopmental outcomes, MRI and health economics.
Thuật ngữ chủ đề	Pediatric
Từ khóa tự do	Clinical trials; Paediatric infectious disease
Địa chỉ	100Kho Bài báo quốc tế(1): BQT00123
Tệp tin điện tử	https://pubmed.ncbi.nlm.nih.gov/40180374/
Tệp tin điện tử	https://lib.hpmu.edu.vn/kiposdata2/tapchi2026/anhbiatc/biabbqt_thumbimage.jpg

MARC

Hiển thị đầy đủ trường & trường con

Tag	Giá trị
000	00000nab#a2200000ui#4500
001	34053
002	13
004	9FFBAC11-123A-4845-82D9-F258BEEEDEAC
005	202605201442
008	081223s2025 vm\| vie
009	1 0
039	[ ] \|y 20260520144210 \|z phuongntt
041	[ ] \|a Eng
084	[ ] \|a C22
100	[ ] \|a Phan Hữu Phúc
245	[ ] \|a Effectiveness and safety of shortened intensive treatment for children with tuberculous meningitis (SURE): a protocol for a phase 3 randomised controlled trial evaluating 6 months of antituberculosis therapy and 8 weeks of aspirin in Asian and African children with tuberculous meningitis
260	[ ] \|c 2025
260	[ ] \|b BMJ
520	[ ] \|a 400 children (aged 29 days to <18 years) with clinically diagnosed TBM will be randomised, using a factorial design, to either a 24-week intensified regimen (isoniazid (20 mg/kg), rifampicin (30 mg/kg), pyrazinamide (40 mg/kg) and levofloxacin (20 mg/kg)) or the standard 48-week ATT regimen and 8 weeks of high-dose aspirin or placebo. The primary outcome for the first randomisation is all-cause mortality, and for the second randomisation is the paediatric modified Rankin Scale (mRS), both at 48 weeks. Nested substudies include pharmacokinetics, pharmacogenetics, pathophysiology, diagnostics and prognostic biomarkers, in-depth neurodevelopmental outcomes, MRI and health economics.
650	[ ] \|a Pediatric
653	[ ] \|a Clinical trials
653	[ ] \|a Paediatric infectious disease
691	[ ] \|a CTĐT Tiến sĩ Nhi khoa
691	[ ] \|a CTĐT Bác sĩ nội trú Nhi khoa
773	[ ] \|t BMJ Open
852	[ ] \|a 100 \|b Kho Bài báo quốc tế \|j (1): BQT00123
856	[ ] \|u https://pubmed.ncbi.nlm.nih.gov/40180374/
856	[1 ] \|u https://lib.hpmu.edu.vn/kiposdata2/tapchi2026/anhbiatc/biabbqt_thumbimage.jpg
890	[ ] \|a 1 \|b 0 \|c 0 \|d 0

Dòng	Mã vạch	Bản sao	Nơi lưu	Tình trạng	Cho phép yêu cầu
1	BQT00123	1	Kho Bài báo quốc tế
#1 BQT00123 Nơi lưu Kho Bài báo quốc tế Tình trạng

Bình luận